search
Back to results

Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness (POPS3)

Primary Purpose

Pompe Disease

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood sample
Sponsored by
Centre Hospitalier Universitaire de Nice
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Pompe Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Presence of a CV <80% of predicted and / or <LIN
  • Presence spirometry a report Tiffeneau (FEV / CV) equal to or higher than normal
  • Signature of informed consent
  • Men and women age ≥ 18 years
  • Production of a medical examination
  • Affiliated to social security

Exclusion Criteria:

  • restrictive breath traumatic
  • restrictive respiratory failure associated with parenchymal disorder, whether localized or diffuse
  • known neuromuscular disease associated with a restrictive lung disease
  • Patient under guardianship, curatorship, protected by law
  • Inability to cooperate
  • Morbid obesity with a BMI ≥40

Sites / Locations

  • CHU d'Angers
  • Centre hospitalier d'Argenteuil
  • CHU de Brest
  • CH d'Escartons
  • CH de Cannes
  • CHI de Créteil
  • CHU le Bocage
  • CHRU de Lille
  • CHU de Limoges
  • Cabinet Dr Pereira-Cortese
  • CHU de Nice
  • GH Pitié Salpêtrière
  • Hôpital Raymond Poincaré
  • Hôpital Saint Louis
  • Hôpital Tenon
  • Polyclinique les Bleuets
  • CHU de Rouen
  • CHU de St Etienne
  • CHU de Toulouse
  • CHRU de Tours
  • Clinique Saint Joseph

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Restrictive Respiratory Failure

Arm Description

A CPK dosage, muscular questionnaires and a Pompe Disease test are practiced on patient with Restrictive Respiratory Failure without etiology

Outcomes

Primary Outcome Measures

Number of new cases of Pompe disease diagnosed by a positive DBS
Number of new cases of Pompe disease diagnosed by a positive DBS in patients with unexplained restriction pulmonaires.ries volumes, the patient is adressed to a specialist to dertermine etilogy of the muscular disease.

Secondary Outcome Measures

Number of new cases and etiologies of neuromuscular diseases diagnosed in patients with unexplained restriction of lung volumes
If a patient have an high CPK rate or a blotter test positive for Pompe disease or a suspicion of muscular disease with the muscular questionnaires, the patient is addressed to a specialist to determine etiology of the muscular disease.
Frequency and description of neurological symptoms associated with neuromuscular diseases to respiratory revelation
If a patient have an high CPK rate or a suspicion of muscular disease with the muscular questionnaires, the patient is addressed to a specialist to determine etiology of the muscular disease.

Full Information

First Posted
April 12, 2016
Last Updated
March 20, 2023
Sponsor
Centre Hospitalier Universitaire de Nice
search

1. Study Identification

Unique Protocol Identification Number
NCT02746718
Brief Title
Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness
Acronym
POPS3
Official Title
Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
December 11, 2015 (Actual)
Primary Completion Date
December 11, 2019 (Actual)
Study Completion Date
December 11, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nice

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A breach of respiratory function may be one of the elements more or less early or predominant clinical picture of neuromuscular diseases. It is considered that the obstructive syndromes represent 64% and restrictive or mixed syndromes 36% of chronic respiratory insufficiency, approximately 7% due to a neuromuscular disease. The frequency and type of impairment are dependent on the underlying pathology. The neuromuscular restrictive respiratory failure (IRR) remains partially unknown pulmonologists, especially because the signs of muscle weakness are sometimes difficult to detect. However, respiratory diseases are a major concern in neuromuscular diseases because they can have an impact both on sleep (not sleep, ...) on the daily activities (breathlessness on exertion, dyspnea) and thereby alter the quality of life of patients. Moreover, they represent a significant morbidity and mortality factor. Chest tightness may in some cases reveal the disease and thus constitute the chief complaint of a patient with a neuromuscular disease. In late-onset Pompe disease, lung disease is the predominant clinical symptoms in about 30% of patients. An algorithm was developed to guide practitioners and help them in their diagnostic approach to the cause of the IRR (diagnostic algorithm ATS / ERS 2005). However, this algorithm does not allow precise identification of the neuromuscular causes. At the patient level, this can have an impact by extending the time before placing a diagnosis. In Pompe disease, the average time to diagnosis reached 7.9 years. However, there are for this disease a simple and rapid diagnostic test. Therefore, a greater awareness of practitioners with regard to the particular Pompe disease and neuromuscular diseases in general may be beneficial to patients. This study aims to: i) awareness pulmonologists to the possibility of neuromuscular an IRR. ii) characterize the frequency of neuromuscular origin of IRR in a broad population of patients with concomitant signs muscle weakness. iii) reduce the time to diagnosis by directing patients to neuromuscular reference center early.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pompe Disease

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Restrictive Respiratory Failure
Arm Type
Other
Arm Description
A CPK dosage, muscular questionnaires and a Pompe Disease test are practiced on patient with Restrictive Respiratory Failure without etiology
Intervention Type
Other
Intervention Name(s)
Blood sample
Intervention Description
A blood sample for CPK dosage and pompe disease test
Primary Outcome Measure Information:
Title
Number of new cases of Pompe disease diagnosed by a positive DBS
Description
Number of new cases of Pompe disease diagnosed by a positive DBS in patients with unexplained restriction pulmonaires.ries volumes, the patient is adressed to a specialist to dertermine etilogy of the muscular disease.
Time Frame
At the inclusion
Secondary Outcome Measure Information:
Title
Number of new cases and etiologies of neuromuscular diseases diagnosed in patients with unexplained restriction of lung volumes
Description
If a patient have an high CPK rate or a blotter test positive for Pompe disease or a suspicion of muscular disease with the muscular questionnaires, the patient is addressed to a specialist to determine etiology of the muscular disease.
Time Frame
at 6 month
Title
Frequency and description of neurological symptoms associated with neuromuscular diseases to respiratory revelation
Description
If a patient have an high CPK rate or a suspicion of muscular disease with the muscular questionnaires, the patient is addressed to a specialist to determine etiology of the muscular disease.
Time Frame
at 6 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Presence of a CV <80% of predicted and / or <LIN Presence spirometry a report Tiffeneau (FEV / CV) equal to or higher than normal Signature of informed consent Men and women age ≥ 18 years Production of a medical examination Affiliated to social security Exclusion Criteria: restrictive breath traumatic restrictive respiratory failure associated with parenchymal disorder, whether localized or diffuse known neuromuscular disease associated with a restrictive lung disease Patient under guardianship, curatorship, protected by law Inability to cooperate Morbid obesity with a BMI ≥40
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sabrina Sacconi
Organizational Affiliation
Centre Hospitalier Universitaire de Nice
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU d'Angers
City
Angers
Country
France
Facility Name
Centre hospitalier d'Argenteuil
City
Argenteuil
Country
France
Facility Name
CHU de Brest
City
Brest
ZIP/Postal Code
29609
Country
France
Facility Name
CH d'Escartons
City
Briancon
Country
France
Facility Name
CH de Cannes
City
Cannes
Country
France
Facility Name
CHI de Créteil
City
Créteil
ZIP/Postal Code
94000
Country
France
Facility Name
CHU le Bocage
City
Dijon
Country
France
Facility Name
CHRU de Lille
City
Lille
Country
France
Facility Name
CHU de Limoges
City
Limoges
Country
France
Facility Name
Cabinet Dr Pereira-Cortese
City
Nice
Country
France
Facility Name
CHU de Nice
City
Nice
Country
France
Facility Name
GH Pitié Salpêtrière
City
Paris
Country
France
Facility Name
Hôpital Raymond Poincaré
City
Paris
Country
France
Facility Name
Hôpital Saint Louis
City
Paris
Country
France
Facility Name
Hôpital Tenon
City
Paris
Country
France
Facility Name
Polyclinique les Bleuets
City
Reims
Country
France
Facility Name
CHU de Rouen
City
Rouen
Country
France
Facility Name
CHU de St Etienne
City
Saint-Étienne
ZIP/Postal Code
94000
Country
France
Facility Name
CHU de Toulouse
City
Toulouse
Country
France
Facility Name
CHRU de Tours
City
Tours
ZIP/Postal Code
37044
Country
France
Facility Name
Clinique Saint Joseph
City
Trélazé
ZIP/Postal Code
49800
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness

We'll reach out to this number within 24 hrs